Compare Novartis AG (NVS) vs Union Pacific Corporation (UNP) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Union Pacific (UNP) trades at $288.45, down 0.4% on the day, with a bearish technical signal but strong fundamentals including a 28.85% net income margin and robust cash flow. Recent earnings beats in Q1 and Q2 2026, coupled with a pending Norfolk Southern merger expected to close by late 2027, highlight growth potential. The stock is supported by a consensus analyst price target of $334.33, indicating 16% upside.

The outlook is positive due to solid profitability and merger prospects, but risks include regulatory hurdles for the merger and economic sensitivity. Analysts are predominantly bullish (58.7% buy ratings), though technical indicators suggest near-term caution with support at $287.